Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Hepatology International
Published in: Hepatology International 5/2016

01-09-2016 | Review Article

Hepatitis C virus cell entry: a target for novel antiviral strategies to address limitations of direct acting antivirals

Authors: Che C. Colpitts, Thomas F. Baumert

Published in: Hepatology International | Issue 5/2016

Login to get access

Abstract

Hepatitis C virus (HCV) infection remains a major global health problem, with 130–170 million chronically infected individuals at risk to develop severe liver disease, including hepatocellular carcinoma. Although the development of direct-acting antivirals offers cure for a large majority of patients, there are still a number of clinical challenges. These include DAA failure in a significant subset of patients, difficult-to-treat genotypes and limited access to therapy due to high costs. Moreover, recent data indicate that the risk for liver cancer persists in patients with advanced fibrosis. These challenges highlight the need for continued efforts towards novel therapeutic strategies for HCV. Over the past two decades, advances in HCV model systems have enabled a detailed understanding of HCV entry and its clinical impact. Many of the virus-host interactions involved in HCV entry have now been identified and explored as antiviral targets. Furthermore, viral entry is recognized as an important factor for graft reinfection and establishment of persistent infection. HCV entry inhibitors, therefore, offer promising opportunities to address the limitations of DAAs. Here, we summarize recent advances in the field of HCV entry and discuss perspectives towards the prevention and cure of HCV infection and virus-induced liver disease.
Literature
1.
Thomas DL. Global control of hepatitis C: where challenge meets opportunity. Nat Med 2013;19:850–858
2.
van der Meer AJ, Veldt BJ, Feld JJ, Wedemeyer H et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012;308:2584–2593
3.
Ferenci P, Kozbial K, Mandorfer M, Hofer H. HCV targeting of patients with cirrhosis. J Hepatol 2015;63:1015–1022
4.
Roche B, Coilly A, Roque-Afonso AM, Samuel D. Interferon-free hepatitis C treatment before and after liver transplantation: The role of HCV drug resistance. Viruses 2015;7:5155–5168
5.
Chung RT, Baumert TF. Curing chronic hepatitis C–the arc of a medical triumph. N Engl J Med 2014;370:1576–1578
6.
Colpitts CC, Verrier ER, Baumert TF. Targeting viral entry for treatment of hepatitis B and C virus infections. ACS Infect Dis 2015;1:420–427
7.
Fofana I, Jilg N, Chung RT, Baumert TF. Entry inhibitors and future treatment of hepatitis C. Antiviral Res 2014;104:136–142
8.
Choo QL, Richman KH, Han JH, Berger K et al. Genetic organization and diversity of the hepatitis C virus. Proc Natl Acad Sci USA 1991;88:2451–2455
9.
Chang KS, Jiang J, Cai Z, Luo G. Human apolipoprotein e is required for infectivity and production of hepatitis C virus in cell culture. J Virol 2007;81:13783–13793
10.
Barth H, Schafer C, Adah MI, Zhang F et al. Cellular binding of hepatitis C virus envelope glycoprotein E2 requires cell surface heparan sulfate. J Biol Chem 2003;278:41003–41012
11.
Barth H, Schnober EK, Zhang F, Linhardt RJ et al. Viral and cellular determinants of the hepatitis C virus envelope-heparan sulfate interaction. J Virol 2006;80:10579–10590
12.
Morikawa K, Zhao Z, Date T, Miyamoto M et al. The roles of CD81 and glycosaminoglycans in the adsorption and uptake of infectious HCV particles. J Med Virol 2007;79:714–723
13.
Xu Y, Martinez P, Seron K, Luo G et al. Characterization of hepatitis C virus interaction with heparan sulfate proteoglycans. J Virol 2015;89:3846–3858
14.
Jiang J, Cun W, Wu X, Shi Q et al. Hepatitis C virus attachment mediated by apolipoprotein E binding to cell surface heparan sulfate. J Virol 2012;86:7256–7267
15.
Lefevre M, Felmlee DJ, Parnot M, Baumert TF et al. Syndecan 4 is involved in mediating HCV entry through interaction with lipoviral particle-associated apolipoprotein E. PLoS One 2014;9:e95550
16.
Monazahian M, Bohme I, Bonk S, Koch A et al. Low density lipoprotein receptor as a candidate receptor for hepatitis C virus. J Med Virol 1999;57:223–229
17.
Agnello V, Abel G, Elfahal M, Knight GB et al. Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor. Proc Natl Acad Sci USA 1999;96:12766–12771
18.
Molina S, Castet V, Fournier-Wirth C, Pichard-Garcia L et al. The low-density lipoprotein receptor plays a role in the infection of primary human hepatocytes by hepatitis C virus. J Hepatol 2007;46:411–419
19.
Owen DM, Huang H, Ye J, Gale MJ. Apolipoprotein E on hepatitis C virion facilitates infection through interaction with low-density lipoprotein receptor. Virology 2009;394:99–108
20.
Dao Thi VL, Dreux M, Cosset FL. Scavenger receptor class B type I and the hypervariable region-1 of hepatitis C virus in cell entry and neutralisation. Expert Rev Mol Med 2011;13:e13
21.
Scarselli E, Ansuini H, Cerino R, Roccasecca RM et al. The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus. EMBO J 2002;21:5017–5025
22.
Zeisel MB, Koutsoudakis G, Schnober EK, Haberstroh A et al. Scavenger receptor class B type I is a key host factor for hepatitis C virus infection required for an entry step closely linked to CD81. Hepatology 2007;46:1722–1731
23.
Catanese MT, Ansuini H, Graziani R, Huby T et al. Role of scavenger receptor class B type I in hepatitis C virus entry: kinetics and molecular determinants. J Virol 2010;84:34–43
24.
Pileri P, Uematsu Y, Campagnoli S, Galli G et al. Binding of hepatitis C virus to CD81. Science 1998;282:938–941
25.
Bertaux C, Dragic T. Different domains of CD81 mediate distinct stages of hepatitis C virus pseudoparticle entry. J Virol 2006;80:4940–4948
26.
Farquhar MJ, Hu K, Harris HJ, Davis C et al. Hepatitis C virus induces CD81 and claudin-1 endocytosis. J Virol 2012;86:4305–4316
27.
Lupberger J, Zeisel MB, Xiao F, Thumann C et al. EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy. Nat Med 2011;17:589–595
28.
Brazzoli M, Bianchi A, Filippini S, Weiner A et al. CD81 is a central regulator of cellular events required for hepatitis C virus infection of human hepatocytes. J Virol 2008;82:8316–8329
29.
Zona L, Lupberger J, Sidahmed-Adrar N, Thumann C et al. HRas signal transduction promotes hepatitis C virus cell entry by triggering assembly of the host tetraspanin receptor complex. Cell Host Microbe 2013;13:302–313
30.
Evans MJ, von Hahn T, Tscherne DM, Syder AJ et al. Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature 2007;446:801–805
31.
Ploss A, Evans MJ, Gaysinskaya VA, Panis M et al. Human occludin is a hepatitis C virus entry factor required for infection of mouse cells. Nature 2009;457:882–886
32.
Harris HJ, Davis C, Mullins JG, Hu K et al. Claudin association with CD81 defines hepatitis C virus entry. J Biol Chem 2010;285:21092–21102
33.
Benedicto I, Molina-Jimenez F, Bartosch B, Cosset FL et al. The tight junction-associated protein occludin is required for a postbinding step in hepatitis C virus entry and infection. J Virol 2009;83:8012–8020
34.
Sainz BJ, Barretto N, Martin DN, Hiraga N et al. Identification of the Niemann-Pick C1-like 1 cholesterol absorption receptor as a new hepatitis C virus entry factor. Nat Med 2012;18:281–285
35.
Martin DN, Uprichard SL. Identification of transferrin receptor 1 as a hepatitis C virus entry factor. Proc Natl Acad Sci USA 2013;110:10777–10782
36.
Wu X, Lee EM, Hammack C, Robotham JM et al. Cell death-inducing DFFA-like effector b is required for hepatitis C virus entry into hepatocytes. J Virol 2014;88:8433–8444
37.
Park C, Min S, Park EM, Lim YS et al. Pim kinase interacts with nonstructural 5A protein and regulates hepatitis C virus entry. J Virol 2015;89:10073–10086
38.
Gerold G, Meissner F, Bruening J, Welsch K et al. Quantitative proteomics identifies serum response factor binding protein 1 as a host factor for hepatitis C virus entry. Cell Rep 2015;12:864–878
39.
Lavillette D, Bartosch B, Nourrisson D, Verney G et al. Hepatitis C virus glycoproteins mediate low pH-dependent membrane fusion with liposomes. J Biol Chem 2006;281:3909–3917
40.
Kong L, Giang E, Nieusma T, Kadam RU et al. Hepatitis C virus E2 envelope glycoprotein core structure. Science 2013;342:1090–1094
41.
Khan AG, Whidby J, Miller MT, Scarborough H et al. Structure of the core ectodomain of the hepatitis C virus envelope glycoprotein 2. Nature 2014;509:381–384
42.
Perin PM, Haid S, Brown RJ, Doerrbecker J et al. Flunarizine prevents hepatitis C virus membrane fusion in a genotype-dependent manner by targeting the potential fusion peptide within E1. Hepatology 2015; doi:10.​1002/​hep.​28111
43.
Timpe JM, Stamataki Z, Jennings A, Hu K et al. Hepatitis C virus cell-cell transmission in hepatoma cells in the presence of neutralizing antibodies. Hepatology 2008;47:17–24
44.
Catanese MT, Loureiro J, Jones CT, Dorner M et al. Different requirements for scavenger receptor class B type I in hepatitis C virus cell-free versus cell-to-cell transmission. J Virol 2013;87:8282–8293
45.
Witteveldt J, Evans MJ, Bitzegeio J, Koutsoudakis G et al. CD81 is dispensable for hepatitis C virus cell-to-cell transmission in hepatoma cells. J Gen Virol 2009;90:48–58
46.
Hueging K, Doepke M, Vieyres G, Bankwitz D et al. Apolipoprotein E codetermines tissue tropism of hepatitis C virus and is crucial for viral cell-to-cell transmission by contributing to a postenvelopment step of assembly. J Virol 2014;88:1433–1446
47.
Brown RS. Hepatitis C and liver transplantation. Nature 2005;436:973–978
48.
Fafi-Kremer S, Fofana I, Soulier E, Carolla P et al. Viral entry and escape from antibody-mediated neutralization influence hepatitis C virus reinfection in liver transplantation. J Exp Med 2010;207:2019–2031
49.
Fofana I, Fafi-Kremer S, Carolla P, Fauvelle C et al. Mutations that alter use of hepatitis C virus cell entry factors mediate escape from neutralizing antibodies. Gastroenterology 2012;143:223–233.e9
50.
Grove J, Nielsen S, Zhong J, Bassendine MF et al. Identification of a residue in hepatitis C virus E2 glycoprotein that determines scavenger receptor BI and CD81 receptor dependency and sensitivity to neutralizing antibodies. J Virol 2008;82:12020–12029
51.
Mensa L, Crespo G, Gastinger MJ, Kabat J et al. Hepatitis C virus receptors claudin-1 and occludin after liver transplantation and influence on early viral kinetics. Hepatology 2011;53:1436–1445
52.
Curry MP, O’Leary JG, Bzowej N, Muir AJ et al. Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis. N Engl J Med 2015;373:2618–2628
53.
Ferenci P. Treatment of hepatitis C in difficult-to-treat patients. Nat Rev Gastroenterol Hepatol 2015;12:284–292
54.
Mailly L, Xiao F, Lupberger J, Wilson GK et al. Clearance of persistent hepatitis C virus infection in humanized mice using a claudin-1-targeting monoclonal antibody. Nat Biotechnol 2015;33:549–554
55.
Xiao F, Fofana I, Thumann C, Mailly L et al. Synergy of entry inhibitors with direct-acting antivirals uncovers novel combinations for prevention and treatment of hepatitis C. Gut 2015;64:483–494
56.
Padmanabhan P, Dixit NM. Modeling suggests a mechanism of synergy between hepatitis C virus entry inhibitors and drugs of other classes. CPT Pharmacometrics Syst Pharmacol 2015;4:445–453
57.
Xiao F, Fofana I, Heydmann L, Barth H et al. Hepatitis C virus cell-cell transmission and resistance to direct-acting antiviral agents. PLoS Pathog 2014;10:e1004128
58.
Vercauteren K, Brown RJ, Mesalam AA, Doerrbecker J et al. Targeting a host-cell entry factor barricades antiviral-resistant HCV variants from on-therapy breakthrough in human-liver mice. Gut 2015; doi: 10.​1136/​gutjnl-2014-309045
59.
Basu A, Kanda T, Beyene A, Saito K et al. Sulfated homologues of heparin inhibit hepatitis C virus entry into mammalian cells. J Virol 2007;81:3933–3941
60.
Ciesek S, von Hahn T, Colpitts CC, Schang LM et al. The green tea polyphenol, epigallocatechin-3-gallate, inhibits hepatitis C virus entry. Hepatology 2011;54:1947–1955
61.
Calland N, Albecka A, Belouzard S, Wychowski C et al. (-)-Epigallocatechin-3-gallate is a new inhibitor of hepatitis C virus entry. Hepatology 2012;55:720–729
62.
Colpitts CC, Schang LM. A small molecule inhibits virion attachment to heparan sulfate- or sialic acid-containing glycans. J Virol 2014;88:7806–7817
63.
Liu S, Chen R, Hagedorn CH. Tannic acid inhibits hepatitis C virus entry into Huh7.5 cells. PLoS One 2015;10:e0131358
64.
Hsu WC, Chang SP, Lin LC, Li CL et al. Limonium sinense and gallic acid suppress hepatitis C virus infection by blocking early viral entry. Antiviral Res 2015;118:139–147
65.
Calland N, Sahuc ME, Belouzard S, Pene V et al. Polyphenols inhibit hepatitis C virus entry by a new mechanism of action. J Virol 2015;89:10053–10063
66.
Al Olaby RR, Cocquerel L, Zemla A, Saas L et al. Identification of a novel drug lead that inhibits HCV infection and cell-to-cell transmission by targeting the HCV E2 glycoprotein. PLoS One 2014;9:e111333
67.
Yu F, Wang Q, Zhang Z, Peng Y et al. Development of oleanane-type triterpenes as a new class of HCV entry inhibitors. J Med Chem 2013;56:4300–4319
68.
Lin LT, Chung CY, Hsu WC, Chang SP et al. Saikosaponin b2 is a naturally occurring terpenoid that efficiently inhibits hepatitis C virus entry. J Hepatol 2015;62:541–548
69.
Meuleman P, Hesselgesser J, Paulson M, Vanwolleghem T et al. Anti-CD81 antibodies can prevent a hepatitis C virus infection in vivo. Hepatology 2008;48:1761–1768
70.
Meuleman P, Catanese MT, Verhoye L, Desombere I et al. A human monoclonal antibody targeting scavenger receptor class B type I precludes hepatitis C virus infection and viral spread in vitro and in vivo. Hepatology 2012;55:364–372
71.
Lacek K, Vercauteren K, Grzyb K, Naddeo M et al. Novel human SR-BI antibodies prevent infection and dissemination of HCV in vitro and in humanized mice. J Hepatol 2012;57:17–23
72.
Law M, Maruyama T, Lewis J, Giang E et al. Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge. Nat Med 2008;14:25–27
73.
Perotti M, Mancini N, Diotti RA, Tarr AW et al. Identification of a broadly cross-reacting and neutralizing human monoclonal antibody directed against the hepatitis C virus E2 protein. J Virol 2008;82:1047–1052
74.
Owsianka A, Tarr AW, Juttla VS, Lavillette D et al. Monoclonal antibody AP33 defines a broadly neutralizing epitope on the hepatitis C virus E2 envelope glycoprotein. J Virol 2005;79:11095–11104
75.
Meuleman P, Bukh J, Verhoye L, Farhoudi A et al. In vivo evaluation of the cross-genotype neutralizing activity of polyclonal antibodies against hepatitis C virus. Hepatology 2011;53:755–762
76.
Vanwolleghem T, Bukh J, Meuleman P, Desombere I et al. Polyclonal immunoglobulins from a chronic hepatitis C virus patient protect human liver-chimeric mice from infection with a homologous hepatitis C virus strain. Hepatology 2008;47:1846–1855
77.
Liu S, McCormick KD, Zhao W, Zhao T et al. Human apolipoprotein E peptides inhibit hepatitis C virus entry by blocking virus binding. Hepatology 2012;56:484–491
78.
Fofana I, Krieger SE, Grunert F, Glauben S et al. Monoclonal anti-claudin 1 antibodies prevent hepatitis C virus infection of primary human hepatocytes. Gastroenterology 2010;139:953–964, 964.e1
79.
Yamashita M, Iida M, Tada M, Shirasago Y et al. Discovery of anti-claudin-1 antibodies as candidate therapeutics against hepatitis C virus. J Pharmacol Exp Ther 2015;353:112–118
80.
Paciello R, Urbanowicz RA, Riccio G, Sasso E et al. Novel human anti-claudin 1 monoclonal antibodies inhibit HCV infection and may synergize with anti-SRB1 mAb. J Gen Virol 2015; doi:10.​1099/​jgv.​0.​000330
81.
Fukasawa M, Nagase S, Shirasago Y, Iida M et al. Monoclonal antibodies against extracellular domains of claudin-1 block hepatitis C virus infection in a mouse model. J Virol 2015;89:4866–4879
82.
Si Y, Liu S, Liu X, Jacobs JL et al. A human claudin-1-derived peptide inhibits hepatitis C virus entry. Hepatology 2012;56:507–515
83.
Syder AJ, Lee H, Zeisel MB, Grove J et al. Small molecule scavenger receptor BI antagonists are potent HCV entry inhibitors. J Hepatol 2011;54:48–55
84.
Blaising J, Levy PL, Polyak SJ, Stanifer M et al. Arbidol inhibits viral entry by interfering with clathrin-dependent trafficking. Antiviral Res 2013;100:215–219
85.
Blaising J, Levy PL, Gondeau C, Phelip C et al. Silibinin inhibits hepatitis C virus entry into hepatocytes by hindering clathrin-dependent trafficking. Cell Microbiol 2013;15:1866–1882
86.
He S, Lin B, Chu V, Hu Z et al. Repurposing of the antihistamine chlorcyclizine and related compounds for treatment of hepatitis C virus infection. Sci Transl Med 2015;7:282ra49
87.
Liu R, Tewari M, Kong R, Zhang R et al. A peptide derived from hepatitis C virus E2 envelope protein inhibits a post-binding step in HCV entry. Antiviral Res 2010;86:172–179
88.
Vausselin T, Calland N, Belouzard S, Descamps V et al. The antimalarial ferroquine is an inhibitor of hepatitis C virus. Hepatology 2013;58:86–97
89.
Bush CO, Pokrovskii MV, Saito R, Morganelli P et al. A small-molecule inhibitor of hepatitis C virus infectivity. Antimicrob Agents Chemother 2014;58:386–396
90.
Baldick CJ, Wichroski MJ, Pendri A, Walsh AW et al. A novel small molecule inhibitor of hepatitis C virus entry. PLoS Pathog 2010;6:e1001086
91.
Vigant F, Santos NC, Lee B. Broad-spectrum antivirals against viral fusion. Nat Rev Microbiol 2015;13:426–437
92.
St Vincent MR, Colpitts CC, Ustinov AV, Muqadas M et al. Rigid amphipathic fusion inhibitors, small molecule antiviral compounds against enveloped viruses. Proc Natl Acad Sci USA 2010;107:17339–17344
93.
Colpitts CC, Ustinov AV, Epand RF, Epand RM et al. 5-(Perylen-3-yl)ethynyl-arabino-uridine (aUY11), an arabino-based rigid amphipathic fusion inhibitor, targets virion envelope lipids to inhibit fusion of influenza virus, hepatitis C virus, and other enveloped viruses. J Virol 2013;87:3640–3654
94.
Chamoun-Emanuelli AM, Pecheur EI, Simeon RL, Huang D et al. Phenothiazines inhibit hepatitis C virus entry, likely by increasing the fluidity of cholesterol-rich membranes. Antimicrob Agents Chemother 2013;57:2571–2581
95.
Chamoun-Emanuelli AM, Pecheur EI, Chen Z. Benzhydrylpiperazine compounds inhibit cholesterol-dependent cellular entry of hepatitis C virus. Antiviral Res 2014;109:141–148
96.
Anggakusuma, Colpitts CC, Schang LM, Rachmawati H et al. Turmeric curcumin inhibits entry of all hepatitis C virus genotypes into human liver cells. Gut 2014;63:1137–1149
97.
Pollock S, Nichita NB, Bohmer A, Radulescu C et al. Polyunsaturated liposomes are antiviral against hepatitis B and C viruses and HIV by decreasing cholesterol levels in infected cells. Proc Natl Acad Sci USA 2010;107:17176–17181
98.
Ikeda M, Abe K, Yamada M, Dansako H et al. Different anti-HCV profiles of statins and their potential for combination therapy with interferon. Hepatology 2006;44:117–125
99.
Wolf MC, Freiberg AN, Zhang T, Akyol-Ataman Z et al. A broad-spectrum antiviral targeting entry of enveloped viruses. Proc Natl Acad Sci USA 2010;107:3157–3162
100.
Vigant F, Lee J, Hollmann A, Tanner LB et al. A mechanistic paradigm for broad-spectrum antivirals that target virus-cell fusion. PLoS Pathog 2013;9:e1003297
Metadata
Title
Hepatitis C virus cell entry: a target for novel antiviral strategies to address limitations of direct acting antivirals
Authors
Che C. Colpitts
Thomas F. Baumert
Publication date
01-09-2016
Publisher
Springer India
Published in
Hepatology International / Issue 5/2016
Print ISSN: 1936-0533
Electronic ISSN: 1936-0541
DOI
https://doi.org/10.1007/s12072-016-9724-7

Other articles of this Issue 5/2016

Hepatology International 5/2016 Go to the issue

Editorial

Targeting the renin–angiotensin system in liver fibrosis

Original Article

End-stage liver disease patients with MELD >40 have higher waitlist mortality compared to Status 1A patients

Original Article

Twelve-week ribavirin-free direct-acting antivirals for treatment-experienced Chinese with HCV genotype 1b infection including cirrhotic patients

Guidelines

APASL consensus statements and recommendation on treatment of hepatitis C

Editorial

HBsAg loss in chronic hepatitis B: pointers to the benefits of curative therapy

Original Article

HBsAg loss in a New Zealand community study with 28-year follow-up: rates, predictors and long-term outcomes
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits